SS-31

Plain-English version: SS-31 is a tiny lab-made peptide designed to do one job — get inside your mitochondria and protect the part that makes energy. "SS" stands for Szeto-Schiller, the two scientists (Hazel Szeto and Peter Schiller) whose lab at Weill Cornell created this class of "aromatic-cationic" peptides. Its full drug name is elamipretide; you may also see it called Bendavia or MTP-131 in older papers.

What makes it unusual is where it goes. Most molecules float around the whole cell. SS-31 carries a built-in positive charge that pulls it toward the negatively charged inner mitochondrial membrane, where it concentrates heavily — and it does this without depending on the mitochondrion's membrane voltage, which matters because sick mitochondria often lose that voltage.^[1] Its amino-acid sequence is D-Arg-Dmt-Lys-Phe-NH2 (that "Dmt" is a modified tyrosine), and that alternating aromatic-plus-charged pattern is the whole design trick.^[1]

The regulatory reality, stated up front: after roughly two decades of development by Stealth BioTherapeutics, elamipretide finally crossed the finish line for a single, ultra-rare indication. On September 19, 2025 the FDA granted accelerated approval to elamipretide HCl — marketed as FORZINITY — as the first-ever therapy for Barth syndrome, in adults and children weighing at least 30 kg.^[7] "Accelerated approval" is a conditional pathway: the FDA still requires Stealth to run a confirmatory trial to prove the benefit holds up. Crucially, this approval does not cover anti-aging, heart failure, kidney disease, or any general wellness use. The "SS-31" sold by research-chemical vendors for longevity is not the approved drug and is not sanctioned for those purposes. For the broader legal picture, see Are Peptides Legal?

Takeaway first: SS-31 protects cardiolipin, a specialized fat that the mitochondrial energy machinery is built around. When cardiolipin is healthy, electrons flow cleanly and you make ATP (cellular energy) efficiently. When it gets damaged — by age, disease, or lack of oxygen — electrons leak, energy output falls, and you generate more reactive oxygen species (ROS, or "free radicals"). SS-31 steps in to keep cardiolipin doing its job. Here is what the verified research actually shows.

1. Cardiolipin binding — the core mechanism

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane, where it helps organize the electron-transport-chain complexes and shapes the folded membrane structures called cristae. SS-31 selectively binds cardiolipin and, critically, prevents cardiolipin from converting cytochrome c — normally an electron carrier — into a peroxidase, an enzyme that would otherwise generate damaging oxidants and trigger cell death.^[1] By protecting that interaction, SS-31 preserves cristae structure and keeps oxidative phosphorylation (the ATP-making process) running. Evidence level: biochemical and cell-based mechanistic work, summarized in a review — not a human trial.

2. Re-energizing injured mitochondria (animal evidence)

The mechanism has been demonstrated in living animals. In a rat model of kidney ischemia-reperfusion (cutting off blood flow, then restoring it — a classic way to injure mitochondria), SS-31 given beforehand protected the cristae, prevented mitochondria from swelling, sped up ATP recovery when blood flow returned, blocked apoptosis (programmed cell death), and reduced the resulting kidney dysfunction.^[2] This study is the clearest in-vivo confirmation that the cardiolipin mechanism translates into protected, better-functioning mitochondria. Evidence level: rats.

3. Restoring bioenergetics in heart-failure models (animal evidence)

In dogs with experimentally induced advanced heart failure, three months of daily elamipretide restored mitochondrial respiration, membrane potential, and ATP synthesis, and this tracked with improved heart function.^[3] Again, this shows the mechanism produces measurable functional gains — in animals. Evidence level: dogs.

Why this is different from a regular antioxidant

Vitamin C and vitamin E scavenge free radicals after they are already floating around the cell. SS-31 works upstream: by keeping electron transport efficient, it reduces how many reactive oxygen species get produced in the first place, right at the mitochondrial source.^[1] That "fix the leak instead of mopping the floor" framing is the whole appeal of the molecule.

What we do NOT know

The mechanism is genuinely well-characterized — but a clean mechanism is not the same as a clinical benefit. As you will see in the next section, when SS-31 was tested in large, rigorous human trials, the mechanistic promise did not consistently translate into the outcomes that were measured. Human pharmacokinetics exist from the trial program, but there is no validated human dose or protocol for any anti-aging or general-wellness use.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. SS-31 is unusual among research peptides in that it has real, published, randomized human trials — so we can be more concrete than usual. The catch is that several of those trials were negative. We report the misses as plainly as the hits.

Barth syndrome — the one approved use

Claim: improves muscle strength and function in Barth syndrome, a rare genetic disorder where a faulty tafazzin gene wrecks cardiolipin remodeling. Mechanism: direct cardiolipin protection compensates for the defect. Population: the TAZPOWER phase 2/3 trial — 12 genetically confirmed patients (all male, mean age about 19.5), 40 mg subcutaneously once daily. Effect: in the randomized, placebo-controlled crossover phase, neither primary endpoint was met — not the 6-minute walk test and not the BTHS-SA fatigue score. Improvements only appeared later, in the uncontrolled open-label extension: 6-minute walk distance rose by about 95.9 m (p=0.024), fatigue score improved by 2.1 points (p=0.031), knee-extensor strength jumped roughly 42% (p=0.001), and left-ventricular stroke volume rose about 16%.^[4] A 168-week open-label extension reported those gains were sustained with continued tolerability.^[5] Limitation: the positive numbers all come from open-label (unblinded, uncontrolled) data — the gold-standard randomized comparison was negative. The FDA's accelerated approval leaned on the open-label muscle-strength data and still requires a confirmatory trial.^[7]

Primary mitochondrial myopathy — a large negative trial

Claim: would improve walking distance and fatigue in people with genetic mitochondrial muscle disease. Mechanism: restore mitochondrial energy output in chronically under-powered muscle. Population: MMPOWER-3, a well-powered phase 3 randomized controlled trial — 218 patients across 27 centers in 7 countries. Effect: it failed both primary endpoints. The 6-minute walk difference versus placebo was −3.2 m (95% CI −18.7 to 12.3; p=0.69), and the PMMSA total fatigue score showed no benefit (p=0.37).^[6] Limitation: this is a large, rigorous, honest negative result — and it is the single most important counterweight to marketing claims that SS-31 reliably boosts energy or endurance in people. When the mechanism was put to its fairest human test, it did not deliver on the measured outcomes.

Heart failure — mechanism yes, human endpoints no

Claim: would improve heart function in heart failure. Mechanism: restored mitochondrial respiration and ATP synthesis in cardiac muscle. Population: dogs with microembolization-induced heart failure (14 animals) received elamipretide 0.5 mg/kg subcutaneously daily for 3 months. Effect: in the animal work, ejection fraction rose (from 30±2% to 36±2%, p<0.05) while controls declined, NT-proBNP (a heart-strain marker) fell by roughly 774 pg/mL, and mitochondrial function was restored.^[3] Limitation: those are dog data. Subsequent human heart-failure trials largely failed their primary endpoints, so the encouraging animal cardiology has not carried over into proven human benefit.

Kidney protection — animal-stage

Claim: would protect kidneys from mitochondrial injury. Mechanism: preserving cristae and speeding ATP recovery after loss of blood flow. Population: rats with renal ischemia-reperfusion injury. Effect: SS-31 pretreatment protected mitochondrial structure, prevented swelling, and reduced kidney dysfunction.^[2] Limitation: rodent data only; no approved or proven human renal use.

Anti-aging and longevity — the honest status

Claim: would reverse age-related mitochondrial decline in muscle, heart, and other tissues. Mechanism: because mitochondrial dysfunction is a recognized hallmark of aging, protecting cardiolipin is a biologically reasonable anti-aging lever. Population: aged animals in preclinical studies. Effect: preclinical aging work has reported restored function in several tissues, which is what drives longevity interest. Limitation: there is no human anti-aging trial demonstrating a longevity or healthspan benefit, and the most relevant human muscle/endurance trial (MMPOWER-3) was negative.^[6] So the accurate framing is "mechanistically attractive, supported in animals, unproven for anti-aging in people." For adjacent longevity approaches, see MOTS-c, NAD+, and the full anti-aging peptides overview.

The honest bottom line on benefits

• One narrow FDA approval (Barth syndrome, accelerated, confirmatory trial pending) — not general validation.^[7]
• The best-powered human trials were negative or missed their primary endpoints. Positive human data are largely from small, open-label, uncontrolled extensions.
• The mechanism is real and well-documented — in cells and animals — but mechanism has repeatedly outrun measured human outcomes here.
• Anti-aging use is preclinical. No human longevity trial supports it.

Read this first: the only clinically validated dose is the one in the approved drug label for Barth syndrome, and that is a prescription medicine (FORZINITY) used under medical supervision — not a self-directed protocol. The trial dose across the Barth and myopathy programs was 40 mg subcutaneously once daily.^[4][6] The lower "research" doses you see for anti-aging are extrapolations, not trial-validated figures. We describe dosing here for education and harm reduction, not as medical guidance.

Doses used in research (by setting)

Setting	Dose	Route & frequency	Source
Barth syndrome (TAZPOWER)	40 mg	Subcutaneous, once daily	Human phase 2/3[4]
Mitochondrial myopathy (MMPOWER-3)	40 mg	Subcutaneous, once daily	Human phase 3[6]
Heart failure (canine model)	0.5 mg/kg	Subcutaneous, once daily	Animal[3]
"Anti-aging" research use	~5–10 mg (varies)	Subcutaneous, once daily	Extrapolated — not trial-validated

Notice the human trials converged on 40 mg daily subcutaneously. The much lower figures circulating in longevity forums are inferred from animal work and have no human efficacy data behind them.

Why once-daily works

SS-31 concentrates in the inner mitochondrial membrane within minutes of reaching the tissue, and it is not a receptor agonist that desensitizes with repeated exposure. That rapid targeting is why once-daily dosing was used in the trials despite the peptide's relatively short time in the bloodstream, and why there is no established need for cycling.^[1]

Reconstitution math, with a worked example

Research-grade SS-31 ships as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: take a 50 mg vial and add 2 mL of bacteriostatic water. That gives 50 ÷ 2 = 25 mg/mL. To draw a 5 mg research dose: 5 ÷ 25 = 0.20 mL, which is 20 units on a standard 100-unit insulin syringe. A 10 mg dose is 0.40 mL, or 40 units.

Vial	BAC water	Concentration	5 mg dose	10 mg dose
50 mg	2 mL	25 mg/mL	0.20 mL (20 units)	0.40 mL (40 units)
50 mg	4 mL	12.5 mg/mL	0.40 mL (40 units)	0.80 mL (80 units)
10 mg	1 mL	10 mg/mL	0.50 mL (50 units)	1.0 mL (100 units)

Preparation steps: wipe the vial stopper with alcohol; draw the water; inject it slowly down the inside wall rather than blasting the powder; swirl gently (do not shake) until the solution is clear; label the vial with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a step-by-step walkthrough.

Timing, cycles, and storage

• Timing: no strict meal timing; mitochondrial uptake does not depend on metabolic state. Morning dosing is convention.
• Injection site: abdomen or thigh, subcutaneously, rotating sites — injection-site reactions are the most common issue (see the safety section).
• Cycle length: the trials used continuous daily dosing rather than cycles; research protocols often run 4–12 weeks. Functional changes, where they occur, develop over weeks, not days.
• Storage: keep lyophilized vials cold and dark (freezer for long-term, 2–8°C for months); refrigerate reconstituted solution at 2–8°C and use within about 28 days. See the peptide storage guide.

None of the above is a recommendation to self-administer an unapproved compound. It describes how the research doses are structured.

Straight talk: SS-31 has a genuinely large clinical safety database compared with most research peptides, because it went through multi-year, multi-trial development. The recurring, defining side effect is simple and local — injection-site reactions. Serious systemic toxicity was not a prominent feature of the trials, but "well-studied" does not mean "risk-free," and none of that safety data was collected for anti-aging use.

Reported side effects

Effect	Frequency	Severity	Notes
Injection-site reactions (redness, pain, induration/hardening)	Very common	Mild–moderate	The hallmark adverse event; in TAZPOWER 100% of drug-treated patients had a treatment-emergent adverse event vs 83% on placebo, driven largely by these reactions[4]
Headache	Occasional	Mild	Reported in trial participants
Fatigue	Occasional	Mild	Reported in some participants
Nausea	Occasional	Mild	Typically mild and transient

In the Barth trial, the two discontinuations in the open-label period were due to injection-site reactions rather than any systemic toxicity — a useful signal that the main tolerability limit is local, not organ-level.^[4] Rotating injection sites and proper technique reduce these reactions.

Who should be cautious or avoid it

• Pregnancy and breastfeeding: no adequate human reproductive-safety data — avoid.
• Known hypersensitivity to the peptide or its components.
• Anyone considering it for anti-aging or general wellness: remember that the entire safety record was built in patients with serious mitochondrial disease under medical supervision, not in healthy people self-dosing for longevity. That context does not transfer automatically.
• People on other prescription medications: formal drug-interaction characterization for self-directed use is limited — a reason for medical oversight, not self-experimentation.

The limitations you must keep in mind

• The favorable tolerability comes from supervised clinical trials in a specific patient population — not from healthy-adult longevity use.
• "Research-grade" vials are unregulated; contamination and mislabeling are separate, real hazards independent of the peptide itself.
• Long-term safety of continuous use in healthy people is simply not established.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: there are now effectively two different things called elamipretide/SS-31. One is FORZINITY, an FDA-approved prescription drug for Barth syndrome, dispensed through the medical system with a known identity and purity. The other is "SS-31" sold by research-chemical vendors for longevity — unapproved, unregulated, and variable in quality. Do not confuse the two. The approved drug's safety and efficacy record does not certify a random research vial.

What a credible research product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight for the D-Arg-Dmt-Lys-Phe-NH2 sequence.
• Batch-specific results: the certificate should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial.

Red flags

• No COA, or a certificate from the seller rather than an independent lab
• Pre-mixed "ready to use" liquid (shorter shelf life, contamination risk)
• Prices far below market
• Explicit human-use or medical claims, or any implication it is the same as the approved drug — a sign of a non-compliant vendor

Legal and regulatory status (2026)

• Approved (narrowly): elamipretide received FDA accelerated approval on September 19, 2025 as FORZINITY for Barth syndrome in patients weighing at least 30 kg, with a required confirmatory post-marketing trial.^[7]
• Not approved for general use: there is no approval for anti-aging, heart failure, kidney disease, or wellness. Research-grade "SS-31" sold for those purposes is unapproved.^[7]
• Not a controlled substance: SS-31 is not DEA-scheduled.
• Sports: mitochondrial and performance-adjacent compounds can fall under anti-doping scrutiny; competitive athletes should verify current rules before use.

For the complete legal picture, read Are Peptides Legal?

Quick answer: the two versions cost worlds apart. FORZINITY, the approved orphan drug, is priced like a rare-disease therapy — typically many thousands of dollars per month and accessed only by prescription through specialty channels. Research-grade "SS-31" powder, by contrast, is usually sold in the range of roughly $50–150 per vial (commonly 10–50 mg), plus bacteriostatic water and syringes.

Item	Typical cost
Research-grade vial (10–50 mg)	~$50–150
Bacteriostatic water	$8–15
Insulin syringes (box)	$10–15
FORZINITY (approved drug)	Rare-disease pricing; prescription only

Price should never override a verifiable third-party COA. With an unregulated compound, a cheap, untested vial is the most expensive mistake you can make — and it is worth repeating that a research vial is not the clinically studied, approved medicine.